Business
OKYO Pharma to Ring the Opening Bell at Nasdaq
LONDON and NEW YORK, Dec. 19, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular condition associated with chronic and often severe nerve-related pain but without an FDA-approved therapy, announced that Executive Chairman and Founder, Gabriele Cerrone and the OKYO management team will ring the Opening Bell at the Nasdaq MarketSite in Times Square, New York today.
About this update from Okyo Pharma Limited
[{"type":"image","alt":"OKYO Pharma LTD","displaySize":"","headline":null,"caption":"OKYO Pharma LTD","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":113,"url":"https://media.zenfs.com/en/globenewswire.com/a8bd0cda50c593b9f86805333401781f"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Z5rBQz17s3GxW5mY3tWfBg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1ODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/a8bd0cda50c593b9f86805333401781f","width":300,"height":113}},"lazy":false},{"type":"text","content":"LONDON and NEW YORK, Dec. 19, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular condition associated with chronic and often severe nerve-related pain but without an FDA-approved therapy, announced that Executive Chairman and Founder, Gabriele Cerrone and the OKYO management team will ring the Opening Bell at the Nasdaq MarketSite in Times Square, New York today.","length":499,"tagName":"p"},{"type":"text","content":"The ceremony will be held from 9:15 AM to 9:45 AM ET, and celebrates OKYO's ongoing advancements in innovative treatments, including its lead candidate urcosimod, a lipid-conjugated chemerin peptide agonist targeting the ChemR23 G-protein-coupled receptor. The company's novel approach aims to address a significant unmet need in neuropathic corneal pain (NCP) where there are no FDA-approved therapies currently available.","length":431,"tagName":"p"},{"type":"text","content":""This is a proud moment for OKYO Pharma and a testament to the hard work and dedication of our exceptional team who are working to improve patient outcomes," said Gabriele Cerrone, Executive Chairman and Founder of OKYO Pharma. "Ringing the Nasdaq Opening Bell is a powerful celebration of our unwavering commitment to transforming patient outcomes through groundbreaking therapies for ocular pain. We are excited about the future as we advance our clinical programs and deliver on our mission to address unmet medical needs."","length":546,"tagName":"p"},{"type":"text","content":"OKYO Pharma continues to progress its pipeline, with recent achievements including positive Phase 2 results for urcosimod in neuropathic corneal pain, demonstrating favourable corneal nerve outcomes and p...